Mechanism of the Immune Response to Human Factor VIII in Murine Hemophilia A

Summary

Mice genetically deficient in factor VIII (fVIII) are a model of hemophilia A. As a first step to reproduce in this mouse model what occurs over time in hemophilia A patients treated with human fVIII (hfVIII), we have investigated the time course and the characteristics of their immune response to hfVIII, after multiple intravenous injections. Anti-hfVIII antibodies appeared after four to five injections. They were IgG1 and to a lesser extent IgG2, indicating that they were induced by both Th2 and Th1 cells. Inhibitors appeared after six injections. CD4⁺ enriched splenocytes from hfVIII-treated mice proliferated in response to fVIII and secreted IL-10: in a few mice they secreted also IFN-γ and in one mouse IL-4, but never IL-2. A hfVIII-specific T cell line derived from hfVIII-treated mice secreted both IL-4 and IFN-γ, suggesting that it included both Th1 and Th2 cells. CD4⁺ enriched splenocytes of hfVIII-treated mice recognized all hfVIII domains. Thus, hemophilic mice develop an immune response to hfVIII administered intravenously similar to that of hemophilia A patients. Their anti-hfVIII antibodies can be inhibitors and belong to IgG subclasses homologous to those of inhibitors in hemophilic patients; their anti-hfVIII CD4⁺ cells recognize a complex repertoire and both Th1 and Th2 cytokines, and especially IL-10, may drive the antibody synthesis.

Abbreviations used: antibodies, Ab; antigen presenting cells, APC; Arbitrary Units, AU; enzyme-linked immunosorbant assay, ELISA; factor VIII, fVIII; human factor VIII, hf VIII; intravenous, i.v.; optical density, OD; polymerase chain reaction, PCR; phosphate buffered saline solution, PBS; PBS containing 3% bovine serum albumin, PBS/BSA; PBS containing 0.05% polyoxyethylene sorbitan monolaurate, PBS/Tween-20; phytohemoagglutinin, PHA; stimulation index, SI

Keywords

Factor VIII - inhibitors - T cells - immune response

⁵ Previously known as Bianca M. Conti-Tronconi

• References

• 1 Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-42.
• 2 Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
• 3 Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC. eds Inhibitors to Coagulation Factors. Adv Exp Med Biol 1995; 386: 35-45.
• 4 Aledort LM. Inhibitors in hemophilia patients: current status and management. Am J Hematol 1994; 47: 208-17.
• 5 Bray GL, Kroner BL, Arkin S, Aledort LW, Hilgartner MW, Etster ME, Ragni MV, Goedert JJ. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the multicenter hemophilia cohort study. Am J Hematol 1993; 42: 375-9.
• 6 Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
• 7 Newton-Nash DK, Gill JC, Foster PA. Cellular immune responses to coagulant factor VIII in F.VIII inhibitor patients. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC. eds Inhibitors to Coagulation Factors. Adv Exp Med Biol 1995; 386: 285.
• 8 Singer ST, Addiego Jr. JE, Reason DC, Lucas A. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996; 76: 17-22.
• 9 Reding MT, Wu HY, Krampf M, Okita DK, Diethelm-Okita BM, Key NS, Conti-Fine BM. CD4⁺ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 1999; 82: 509-15.
• 10 Bi L, Lawler AM, Antonarakis SF, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of hemophilia A. Nature Genet 1995; 10: 119-21.
• 11 Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, Bedian V, Kazazian HH. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
• 12 Qian J, Borovok M, Bi L, Kazazian HH, Hoyer LW. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81: 240-4.
• 13 Karachunski PI, Ostlie NS, Monfardini C, Conti-Fine BM. Differential effect on experimental myasthenia gravis in C57Bl/6 mice of absence of Th1 cytokines. J Immunol. 2000 (in press).
• 14 Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 1985; 82: 5131-5.
• 15 Rudensky AY, Preston-Hurburt P, Hong SC, Barlow A, Janeway Jr CA. Sequence analysis of peptide bound to MHC class II molecules. Nature 1991; 353: 622-7.
• 16 Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368: 215-21.
• 17 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eyes J. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
• 18 Bowie EJW, Owen CA. The clinical and laboratory diagnosis of hemorrhagic disorders. In: Disorders of Hemostasis. Ratnoff OD, Forbes CD. eds. Orlando: Grune & Stratton, Inc.; 1984: 43-72.
• 19 Jouvin-Marche E, Morgado MG, Leguern C, Voegtle D, Bonhomme F, Cazenave PA. The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes. Immunogenetics 1989; 29: 92-7.
• 20 Martin RM, Silva A, Lew AM. The Igh-1 sequence of the non-obese diabetic (NOD) mouse assigns it to the IgG2c isotype. Immunogenetics 1997; 46: 167-8.
• 21 Simpson EM, Linder CC, Sargent EE, Davisson MT, Mobraaten LE, Sharp JJ. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nature Genet 1997; 16: 19-27.
• 22 Threadgill DW, Yee D, Matin A, Nadeau JH, Magnuson T. Genealogy of the 129 inbred strains: 129/SvJ is a contaminated inbred strain. Mamm Genome 1997; 8: 390-3.
• 23 Lollar P, Parker ET, Curtis JE, Helgerson SL, Hoyer LW, Scott MF, Scandella D. Inhibition of factor VIIIa by human anti-A2 subunit antibodies. J Clin Invest 1994; 93: 2497-2504.
• 24 Hu-Li J, Ohara J, Watson C, Tsang W, Paul WE. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4S) and of an IL-2 hyporesponsive mutant of that line. J Immunol 1989; 142: 800-7.
• 25 Ohara J, Paul WE. Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature 1985; 315: 333-6.
• 26 Mason D. A very high level of crossreactivity is an essential feature of the T cell receptor. Immunol Today 1998; 19: 395-404.
• 27 Reding MT, Wu HY, Krampf M, Okita DK, Diethelm-Okita BM, Christie BA, Key NS, Conti-Fine BM. Sensitization of CD4⁺ T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 643-52.
• 28 Connelly S, Smith TAG, Dhir G, Gardner JM, Mehaffey MG, Zaret KS, McClelland A, Kaleko M. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995; 6: 185-93.
• 29 Kaufman RJ. Biological regulation of factor VIII activity. Ann Rev Med 1992; 43: 325-39.
• 30 Schwartz RH. Immunological Tolerance. In: Fundamental Immunology. Paul WE. ed. Philadelphia: Lippincott-Raven; 1999: 701-39.
• 31 Jarvis MA, Levin LG, Harrison JA, DePianto DJ, Suzuki CM, Ziaja CL, Brown JE, Jolly KW, Reisner HM, Abildgaard CF, Powell JS. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype. Thromb Haemost 1996; 75: 318-25.
• 32 Dazzi F, Rosato A, Tison T, Vianello F, Radossi P, Girolami A. An animal model to explore the molecular basis of factor VIII (FVIII) inhibitor formation: evidence of anti-FVIII T-cell response and importance of administration route. Thromb Haemost 1995; 73: 1026a.
• 33 Sarkar R, Gao G-P, Chirmule N, Tazelaar J, Kazazian HH. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum Gene Ther 2000; 11: 881-94.
• 34 Elder B, Lakich D, Gitschier J. Sequence of the murine factor VIII cDNA. Genomics 1993; 16: 374-9.
• 35 European Study Group of Factor VIII Antibody. Development of factor VIII antibody in haemophilic monozygotic twins. Scand J Haemat 1979; 23: 64-8.
• 36 Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M. Sustained expression of therapeutic levels of human factor VIII in mice. Blood 1996; 87: 4671-7.
• 37 Connelly S, Andrews JL, Gallo AM, Kayda DB, Qian J, Hoyer L, Kadan MJ, Gorziglia MI, Trapnell BC, McClelland A, Kaleko M. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; 91: 3273-81.
• 38 Balague C, Zhou J, Dai Y, Alemany R, Josephs SF, Andreason G, Hariharan M, Sethi E, Prokopenko E, Jan H-Y, Lou Y-C, Hubert-Leslie D, Ruiz L, Zhang W-W. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000; 95: 820-8.
• 39 Constant SL, Bottomly K. Induction of Th1 and Th2 CD4⁺ T cell responses: The alternative approach. Ann Rev Immunol 1997; 15: 297-322.
• 40 Scandella D. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Vox Sang 1999; 77 suppl 1 17-20.
• 41 Nilsson IM, Berntorp E, Zettervall O, Dahlback B. Noncoagulation inhibitory factor VIII antibody after induction of tolerance to factor VIII in hemophilia A patients. Blood 1990; 75: 378-83.
• 42 Gilles JGG, Arnout J, Vermylen J, Saint-Remy J-MR. Antifactor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.